Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-06-11FDA Approved: LEVETIRACETAM EXTENDED-RELEASE — Original Application (Omnivium Pharmaceuticals LLC)
FDA approved an extended-release generic formulation of levetiracetam (ANDA212688) manufactured by Omnivium Pharmaceuticals LLC.
-
FDA label_change · 2020-06-10FDA Approved: MYSOLINE — Supplemental Application (Bausch Health US, LLC)
FDA approves a supplemental labeling application for Mysoline (primidone) from Bausch Health US, LLC. The action updates the drug's labeling…
-
FDA approval · 2020-06-09FDA Approved: LAMOTRIGINE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Lamotrigine from Amneal Pharmaceuticals LLC, authorizing a new generic lamotrigine product.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex [Phase 2]
A Phase 2 clinical trial investigates aspirin as an add-on treatment for refractory epilepsy in tuberous sclerosis complex.
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy [Phase 3]
Phase 3 follow-up study assessing safety and efficacy of brivaracetam in epilepsy completed; results posted in 2020.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil [Phase 1]
Phase 1 study assessing pharmacokinetics, safety, and tolerability of oxcarbazepine when co-administered with padsevonil in participants wit…
-
FDA approval · 2020-05-19FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) from AbbVie, updating labeling/indications for the pr…
-
FDA approval · 2020-05-19FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie.
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: Evaluation of the Efficacy and Safety of Lacosamide in Pediatric Patients With Epilepsy [Phase 4]
Phase 4 trial evaluating lacosamide for efficacy and safety in pediatric epilepsy patients.
-
CLINICAL_TRIALS trial_result · 2020-05-08Clinical Trial Update: University of Alabama at Birmingham (UAB) Adult CBD Program [Phase 1]
Phase 1 clinical trial update from UAB CBD program investigating effects in epilepsy-related seizures; study completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2020-05-04Clinical Trial Update: Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI [Phase 2]
Phase 2 clinical trial examining abnormal ventilatory response to CO2 as a biomarker for seizure-induced respiratory depression, and how SSR…
-
FDA approval · 2020-04-24FDA Approved: CARBAMAZEPINE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma's original application for carbamazepine, a generic anticonvulsant used to treat epilepsy, trigeminal neuralg…
-
FDA approval · 2020-04-21FDA Approved: VALPROIC ACID — Supplemental Application (Chartwell Governmental & Specialty RX, LLC.)
FDA approved a supplemental application for valproic acid (generic) submitted by Chartwell Governmental & Specialty RX, LLC.
-
FDA approval · 2020-04-20FDA Approved: LEVETIRACETAM — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for Levetiracetam Injection from Dr. Reddy's Laboratories Inc.
-
FDA approval · 2020-04-20FDA Approved: LEVETIRACETAM — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for a generic levetiracetam by Eugia US LLC, enabling its market introduction in the United States.
-
FDA approval · 2020-04-17FDA Approved: VIGABATRIN — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for Vigabatrin submitted by Par Health USA, LLC. This action updates the regulatory status for V…
-
FDA approval · 2020-04-17FDA Approved: VIGADRONE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for VIGADRONE (vigabatrin) from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2020-04-17FDA Approved: VIGABATRIN — Supplemental Application (Dr. Reddys Laboratories Inc.,)
FDA approved a supplemental application for Vigabatrin from Dr. Reddy's Laboratories, marking an update to the product's approval status.
-
FDA approval · 2020-04-17FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approves Amneal Pharmaceuticals NY LLC's supplemental application for Vigabatrin (ANDA210155). This action updates the approval for the …
-
CLINICAL_TRIALS trial_result · 2020-04-16Clinical Trial Update: A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications [Phase 3]
Phase 3 trial comparing lacosamide to placebo in idiopathic generalized epilepsy patients on antiepileptic meds completed with posted result…
-
FDA approval · 2020-04-15FDA Approved: CARBAMAZEPINE — Original Application (NIVAGEN PHARMACEUTICALS, INC.)
The FDA approved the original application for a generic carbamazepine product from NIVAGEN PHARMACEUTICALS, INC., marking the approval of th…
-
FDA approval · 2020-04-13FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
The FDA approved a supplemental application for ZONEGRAN (zonisamide) from Advanz Pharma (US) Corp. This approval authorizes a change to the…
-
CLINICAL_TRIALS trial_result · 2020-04-10Clinical Trial Update: University of Alabama at Birmingham (UAB) Pediatric CBD Program [Phase 1]
Phase 1 clinical trial update for a pediatric CBD program at UAB, completed with results posted in 2020.
-
FDA approval · 2020-04-09FDA Approved: TOPIRAMATE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Topiramate from Zydus Lifesciences Limited under ANDA207382, granting additional approval relate…
-
FDA approval · 2020-04-02FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Neurontin (gabapentin) by Parke-Davis Div of Pfizer Inc, authorizing changes to its labeling…